Printer Friendly

WARNER-LAMBERT, RHONE-POULENC RORER AGREE TO CO-DEVELOP AND CO-PROMOTE ADVANCED QUINOLONE ANTIBACTERIAL IN U.S. AND CANADA

 WARNER-LAMBERT, RHONE-POULENC RORER AGREE TO CO-DEVELOP AND
 CO-PROMOTE ADVANCED QUINOLONE ANTIBACTERIAL IN U.S. AND CANADA
 MORRIS PLAINS, N.J., April 1 /PRNewswire/ -- Warner-Lambert Company (NYSE: WLA) and Rhone-Poulenc Rorer Inc. (NYSE: RPR) today announced an agreement that will allow Rhone-Poulenc Rorer to co-develop and co- promote the advanced quinolone antibacterial sparfloxacin in the United States and Canada.
 Sparfloxacin will soon enter Phase III clinical trials in the U.S. as a treatment for community acquired infections. The compound's investigational indications are community acquired pneumonia, acute exacerbation of chronic bronchitis, complicated urinary tract infection and infections of the skin and skin structure. Warner-Lambert licensed the compound from Dainippon Pharmaceutical Co. Ltd. of Osaka, Japan, in 1989.
 Under the agreement, Rhone-Poulenc Rorer will co-develop sparfloxacin in the U.S. and Canada in exchange for the rights to co-promote the drug in those countries. Rhone-Poulenc Rorer has a joint venture agreement with Dainippon to develop and market sparfloxacin in Europe, and has development and marketing rights in several other countries. Data obtained in the European trials will be used to support the New Drug Application (NDA) in the U.S.
 "We're pleased this partnership has taken shape because it makes maximum use of our resources and has the potential to speed access to the compound," said Warner-Lambert's Joseph E. Smith, executive vice president and president, Pharmaceutical Sector.
 "This agreement has several benefits," said Randy Thurman, executive vice president, RPR, and president, RPR Pharmaceuticals Inc. "It will expand access to sparfloxacin beyond Europe to North America and thereby enable us to maximize the value of this important product. It also will build RPR's portfolio of anti-infectives in the North American market."
 Warner-Lambert will continue to study sparfloxacin in the U.S. for the treatment of Mycobacterium avium complex (MAC) in patients with AIDS. MAC is the most common bacterial infection in AIDS patients.
 Rhone-Poulenc Rorer is a global pharmaceutical company dedicated to the discovery, development, manufacturing and marketing of human pharmaceuticals. The company had sales of $3.8 billion in 1991 and plans to invest approximately $500 million in research and development in 1992.
 Warner-Lambert is a worldwide company devoted to developing, manufacturing and marketing quality health care and consumer products. The company had sales of $5.1 billion in 1991 and plans to invest about $460 million in research and development in 1992.
 -0- 4/1/92
 /CONTACT: Peter Wolf, 201-540-6696, or Stephen Mock, 201-540-6916, or (investors) Cary Rosansky, 201-540-4874, all of Warner Lambert; or Rhone-Poulenc Rorer corporate communications, 215-454-3871, or (investors) 215-454-3851/
 (WLA RPR) CO: Warner-Lambert Company; Rhone-Poulenc Rorer Inc. ST: New Jersey, Pennsylvania IN: MTC SU:


TS -- NY012 -- 3756 04/01/92 09:17 EST
COPYRIGHT 1992 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1992 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Apr 1, 1992
Words:445
Previous Article:THERMO PROCESS SYSTEMS ELECTS DONALD E. NOBLE CHAIRMAN OF THE BOARD
Next Article:KOHL'S ANNOUNCES FILING OF REGISTRATION STATEMENT FOR INITIAL PUBLIC OFFERING
Topics:


Related Articles
RHONE-POULENC RORER AGREES TO SELL $300 MILLION MARKET AUCTION PREFERRED SHARES
RHONE-POULENC RORER AND BOEHRINGER MANNHEIM TO CO-DEVELOP THIRD GENERATION BISPHOSPHONATE.
WARNER-LAMBERT, RHONE-POULENC RORER AGREE TO CO-DEVELOP AND CO-PROMOTE ADVANCED QUINOLONE ANTIBACTERIAL IN U.S. AND CANADA
THE IMMUNE RESPONSE CORPORATION AND RHONE-POULENC RORER INC. COMMIT $18 MILLION ADDITIONAL FUNDING FOR AIDS JOINT VENTURE
ARMOUR PHARMACEUTICAL COMPANY APPOINTS TWO NEW EXECUTIVES
RHONE-POULENC RORER SUB-LICENSES PENETREX(R) ANTIBIOTIC FROM WARNER-LAMBERT AND DAINIPPON FOR NORTH AMERICAN MARKET
RHONE-POULENC RORER (RPR) RECEIVES APPROVABLE LETTER FROM U.S. FDA FOR TAXOTERE(R) (docetaxel)
RHONE-POULENC RORER FILES NEW DRUG APPLICATION FOR SPARFLOXACIN, AN ANTIBIOTIC TO TREAT COMMUNITY-ACQUIRED RESPIRATORY TRACT INFECTIONS
Rhone-Poulenc Rorer Launches New Anti-Infective ZAGAM(R) in U.S.
Rhone-Poulenc Rorer Inc. to Evaluate NanoSystems Drug Delivery Technology For Asthma

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters